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Abstract 
Genome-wide association meta-analysis have now identified more than 150 loci where common 
variants (SNPs) are significantly associated with cardiovascular disease (CVD) and CVD end points. 
These can be used in combination, and “scaled” by their effect size, to create a “weighted” 
Genetic risk Score (GRS), which, in combination with an individual’s classical CVD risk factors, can 
be used to identify those at overall low, intermediate and high future risk.  Those at highest risk 
can be offered life-style and therapeutic options to reduce their risk and those at intermediate 
levels can be monitored. Here we discuss the selection of the best variants to be included in the 
GRS, and the potential utility of such scores in different clinical settings.  115 words 
 
Risk prediction scores using classical risk factors (CRFs) 
A large proportion of CHD events are preventable, therefore, predicting those at highest risk of 
developing the disease is an important public health consideration. To take advantage of the 
combined knowledge of how CRFs affect CHD risk, risk scores have been developed.  The first risk 
score for CHD that gained widespread use was developed from the Framingham Heart Study and 
thus is referred to as the Framingham score [1] Included in it were age, total cholesterol, HDL-
cholesterol, systolic blood pressure, diabetes and smoking (with separate equations for men and 
women). The score showed good predictively ability in some cohorts similar to that from which it 
was derived [2], but it was found to overestimate risk in other ethnic groups [3] and in other 
populations of European ethnicity where there was a lower incidence of CHD  [4, 5].  
In response to this, region-specific scores have been developed such as SCORE which was derived 
using data from 12 prospective European cohorts [6]. The development of large primary care 
electronic records has enabled risk scores to be derived from large population cohorts. In England 
the QRISK score was derived from the QRESEARCH database, (which contains 1.2 million 
individuals) to estimate risk of CVD (rather than CHD) [7]. This score was updated (QRISK2) to 
include a number of other risk factors, most notably self-reported ethnicity [8]. QRISK2 also 
includes measures of social deprivation. This was prompted by the observation that the 
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Framingham score underestimated risk in socially deprived individuals and thus could re-enforce 
social gradients in disease [9]. The QRISK2 model is updated annually (http://www.qrisk.org/).  
 
Primary prevention strategies and Current clinical guidance 
Many of the CRFs for CHD are modifiable and thus lifestyle interventions such as use of smoking 
cessation services and dietary review, form an important part of the strategy to reduce CHD risk. 
Prescription of lipid-lowering therapies, primarily statins, has also been used to compliment this. 
Statin use has been found to reduce risk of CVD events by approximately one fifth per 1mmol/l of 
LDL-cholesterol reduction, in a wide range of individuals [10]. A benefit has also been found in 
those with low CVD risk.  
When risk scores were first introduced into clinical practice, the Framingham risk score was 
recommended for use in both the USA and the UK, with the high risk group being defined as those 
having a ten-year risk of CHD ≥20% [11]. Those who fell into that category were then 
recommended for intensive lifestyle changes and prescription of lipid-lowering medications 
(usually statins). However, the joint guidelines issued by the American College of Cardiology (ACC) 
and the American Heart Association (AHA) developed new risk equations and lowered the high-
risk cut-off to ≥7.5% [12]. Similarly, in the UK the National Institute of Health and Clinical 
Excellence (NICE) updated their guidelines to recommend use of QRISK2 and lowered the high-
risk threshold to ≥10% ([13]. However, given the shortcomings in the available data for statin use 
there have been concerns particularly regarding the “medicalisation of healthy individuals” and 
the numbers of adverse events observed in certain groups [14].There is also evidence that uptake 
of statins in the those classified in the 10-20 % risk group is much lower than estimated by NICE 
[15] although larger studies are required to confirm this.   
However, the majority of cases of CHD/CVD come from individuals classified with average risk 
using the CRF risk scores – the so-called prevention paradox [16]. For example, when  QRISK2 
(2010 version) was validated with data from the health improvement network (THIN), (using a 
20% high-risk cut-off), 14% of men and 6% of women were identified as being at high risk. This 
captured 40% of the cardiovascular events in men and 26% of the cardiovascular events in women 
4 
 
[17]. This leaves scope for refinement of the risk score to discriminate better between those who 
do and do not go on to develop CVD.  
 
Use of genetics in risk prediction 
Data from twin studies has estimated the heritability of CHD mortality to be 40-60% [18,19] 
suggesting that inherited factors are likely to be making a strong contribution to an individual’s 
future risk of premature CVD. The identification of robustly associated CHD risk loci would be 
potentially of interest in risk prediction, since as being fixed at conception, they have a lifelong 
impact and need only be determined once. The first question is thus what genes and what 
common single nucleotide polymorphisms (SNPs) should be included in the genetic risk profile? 
Before 2007, when technology improvements enabled genome-wide association studies (GWAS) 
to address this question in a “hypothesis-free” way, studies in the field used knowledge of the 
pathophysiology of CVD to identify potential “candidate” genes. Combining published small 
studies using meta-analysis [20] lead to the identification of a number of potential candidates 
particularly in the areas of lipid metabolism (eg APOE, APOC3 and LPL). The post-2007 era of 
GWAS identified many previously unknown genomic loci with statistically significant associations 
with CVD, most strikingly with the simultaneous publication in 2007 of three GWAS studies that 
identified a single locus on chromosome 9p.21 [21-23]. This effect has been replicated in countless 
other studies and is an independent CHD risk factor in different ethnic groups [24]. 
To exploit the potential of GWASs to identify risk loci for CHD, the CARDIoGRAMplusC4D 
consortium was set up [25]. A meta-analysis fine-mapping GWAS results for CHD including over 
60,000 cases and 130,000 controls was published identifying more than 50 SNPs from 46 loci that 
were robustly associated with CHD. Reassuringly, many of the original candidate genes have been 
confirmed as GWAS “hits” for CVD, including APOE, APOC3 and LPL. This has been recently 
expanded and a GWAS meta-analysis investigating over 9 million SNPs using haplotype data from 
the 1000 genomes project in approximately 185,000 individuals was recently published [26]  Ten 
new CHD risk loci were identified (eight from an additive model and two from a recessive model).  
Overall, combining published data using meta-analysis, has now led to more than 80 loci that are 
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robustly associated with CHD [27], and for example 30 associated with CHD traits such as coronary 
calcification. (http://www.ebi.ac.uk/gwas/). 
As has been pointed out previously [28],  because of the polygenic nature of CVD, a common SNP 
is usually associated with only a modest risk effect size, while a SNP with a much larger risk effect 
is usually much less common. Table 1 shows a list of 25 GWAS CVD hits with the loci ranked by 
the sum of their effect size (given as an odds ratio (OR)) and their risk allele frequency (RAF) to 
give an overall estimate of their potential clinical utility.  While the ORs range from 1.23 to 1.04 
per risk allele carried, the RAFs for all of these SNPs are high, and overall there is a fourfold 
difference in score from the top to the lowest on this list. Six of these loci are known to be involved 
in lipid metabolism, as would be expected from our knowledge of the importance of dyslipidaemia 
in the development of CVD.  
 It is unlikely that there are any additional common SNPs to be found by GWAS meta-analysis that 
will outrank these 25, since SNPs with larger effects that are common would have been detected 
by the size of the datasets currently available. This means that any CVD SNP panel should 
therefore include all or at least have a good representation of these 25 SNPs or their proxies.  
 
Construction of a “Genetic Risk Score” 
Given the relatively small effect sizes associated with these risk loci, it is unsurprising that the 
addition of one variant into a CRF risk score does not result in improved predictive ability [29-31] 
This has led to the development of so-called “genetic risk scores” (GRSs) where SNPs at 
independent loci are combined. A GRS can be unweighted, where simply the number of risk alleles 
carried by an individual at each locus is summed. This model assumes that the risk effect 
associated with each SNP is equal (and additive) and this clearly is not the case. A more accurate 
GRS can be constructed if carriage of the individual SNPs are weighted using the published effect 
size [32]. An individual’s GRS can be adjusted for the population GRS (based on the RAFs present 
in the population) and then be combined with a CRF score such as the Framingham score or 
QRISK2 [8] to give an overall CHD risk estimate. 
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Using a SNP Genetic Risk Score in men in the UK 
To illustrate the development and use of such a GRS we present data from a UK prospective cohort 
of ~2700 middle-aged men (the Second Northwick Park Hospital study -NPHSII), whose baseline 
characteristics are presented in Table 2. As expected, the men who went on to develop CHD were 
older, had higher BMI, higher systolic blood pressure, higher total cholesterol, LDL cholesterol, 
and a higher proportion were smokers and had diabetes, at baseline. As expected, those who 
subsequently developed CHD had a higher ten-year CHD risk as calculated using the Framingham 
risk score and those who subsequently developed CVD had a higher ten-year CVD risk as 
calculated using the QRISK2 score.   
In 2007 we started to develop a multi-SNP panel using 12 SNPs in candidate genes that, and 
showed that, when used in combination with the Framingham CRF algorithm they had the 
potential to identify individuals at high future risk of CHD [33, 34].  We next showed that, in this 
same cohort, the addition of a single SNP from the chromosome 9p21 GWAS CHD locus, improved 
the CRF area under the receiver operator characteristic curve (AROC) by 3% but that this effect 
was not statistically significant [29].  By mathematical modelling, we estimated that an additional 
three SNPs with similar risk size and RAF would be needed to have a significant improvement [29].  
We therefore developed  a 19 SNP GRS shown in Table 3 comprised of the 9p21 SNP plus six other 
GWAS loci identified at that time, supplemented by 12 common SNPs in candidate genes where 
published meta-analyses, mainly of case-control studies, had demonstrated robust albeit modest 
risk effects. The RAFs for these SNPs varied between 0.01 to 0.9 and the published Odds Ratios 
from 1.1-1.7. The mean of the GRS was significantly higher (p=0.01) in those who went on to 
develop CHD over 13.5 years of follow-up, but there was only a modest and non-significant 
improvement in discrimination (increase in AROC curve p=0.48) and risk classification (net 
reclassification improvement (NRI), p=0.28) compared to the Framingham algorithm alone [35]. 
Similar results were seen if only a 13-SNP GRS including SNPs in loci identified by the 
CARDIoGRAMplusC4D consortium was used. However, the key aspect of clinical utility is in the 
subjects at intermediate risk, since those with a Framingham 10 year CHD risk over 20% qualified 
for statin therapy (under the NICE guidelines at the time), while those at low risk (>10%) did not 
require any intervention. If the addition of the GRS can better discriminate those at intermediate 
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risk who subsequently go on to develop a CHD event then these subjects can be offered 
therapeutic advice and can reduce their subsequent risk. When considering only individuals who 
moved up a risk category with inclusion of the GRS, the improvement in risk classification was 
statistically significant (p=0.01) [35]. Overall these data suggest a modest clinical utility of this 19 
SNP GRS, with its main utility being confined to those at intermediate risk.   
The GSs were originally weighted using the effect sizes determined in meta-analyses of candidate 
gene studies or GWASs. However in the CARDIoGRAMplusC4D meta-analyses the ORs for several 
of the included SNPs had reduced in part because of the so-called “winners curse” [36], and in 
some cases had become non-significant, and the use of these more robust risk estimates should 
improve the clinical utility of the gene score. Also NICE now recommended the use of the QRISK 
algorithm [13] and we found that QRISK2 was better at predicating cardiovascular outcome in 
NPHSII compared to the Framingham score, with the Framingham score overestimating risk and 
showing poor calibration in the NPHSII men [37]. This is consistent with the literature where even 
the NICE-adjusted Framingham risk equations have been found to overestimate ten-year CHD risk 
in the UK population, particularly in men [17]. The superior performance of QRISK2 compared to 
the Framingham score is unsurprising given that QRISK2 was derived from a very large British 
cohort while Framingham was developed from the Framingham study based in Massachusetts, 
USA [1].  As shown in Figure 1A in the NPHSII men 49% were above the 10% 10 year CVD cut-off 
and the event rate in this group was 15.7%. Since 71% of all events occurring in the next 10 years 
were in this high risk group, treatment of all of these subjects is likely to be cost effective. By 
contrast in the 7% of men below 5% 10 year risk there were no CVD events during follow-up.  The 
intermediate group, which constitutes those where clinical judgement is required, represented 
44% of men with an event rate of 7.3%, and it is in this group where better risk stratification would 
be helpful.  
Updating the weightings to those determined in the CARDIoGRAMplusC4D analysis [25] improved 
the performance of the 19 SNP GRS. The weighted 19 SNP GRS was associated with CHD after 
adjustment for CRFs, (OR=1.31 per standard deviation, p=0.03). Not surprisingly since it includes 
seven loci involved in lipid metabolism, the GRS was significantly associated with higher total- and 
LDL-cholesterol and modestly with a reported family history of early CHD (p=0.03). As shown in 
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Figure 1B, 53% of men were now in the high risk group, with 80% of all events being correctly 
identified. Although 1 man in the intermediate risk group incorrectly was assigned to a lower risk, 
116 men (24% of group) moved up from the intermediate to the high risk category, of whom 13 
(11.2%) experienced an event. Overall, addition of the 19 SNP GRS to QRISK2 showed improved 
discrimination (AROC 0.68 v 0.70 p=0.02), and a positive net reclassification index (7%, p=0.04) 
compared to QRISK2 alone.  
Finally, one aim of our work is to identify a minimum SNP data set that will have clinical utility in 
CHD risk stratification, and thus replacing those SNPs which have non-significant CHD risk effects 
with SNPs with larger risk effects should improve clinical utility. To assess if the gene score could 
be improved, we removed five SNPs which had shown little evidence of an association with CHD 
in the CARDIoGRAMplusC4D meta-analysis. We then selected the top seven ranked SNPs from 
those robustly associated with CHD in CARDIoGRAMplusC4D shown in Table 1, discounting those 
in loci already included in the GRS. These were then genotyped in NPHSII and added into the GRS 
to create a 21 SNP GRS. This GRS was strongly associated with CHD even after adjustment for CRFs 
(OR=1.39 per standard deviation, 1.42x10-3), but the combined QRISK2 plus GRS score was poorly 
calibrated (p=0.03) and showed no improvement in discrimination (p=0.55) or reclassification 
(p=0.10) compared to QRISK2 alone [37]. While it is possible that the addition of SNPs who rank 
below these seven may improve clinical utility, the data suggest this improvement is at best likely 
to be modest. However, our results indicate that including the updated weighted 19 SNP GRS 
along with QRISK2 may have clinical utility in the UK population. 
 
Use of a SNP Genetic Risk Score in other studies. 
A number of CHD SNP GRSs have been assessed by others and are shown in Table 4.  In the UCLEB 
consortium of over 25,000 participants and ~2200 events for incident and prevalent CHD, a combined 
QRISK2 plus CARDIoGRAMplusC4D GRS score was used, although it should be noted that QRISK2 
was poorly calibrated in this cohort [38]. Although overall the combined score did not show 
additional benefit over and above QRISK2 alone, the GRS appeared to carry some utility when 
applied only to those who, according to conventional risk scoring, would have been classified at 
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intermediate risk, by moving some individuals who subsequently had an event into the high-risk 
category. The authors estimated that among 100,000 people from a population represented by 
the UCLEB studies, 29,445 would be classed as of intermediate risk according to the QRISK 
equation, and of these, 5,434 would then be reclassified as high risk once the GRS was applied, 
and 1,082 would suffer a CVD event if untreated with statins. Treatment with statins according to 
guidelines could postpone the CVD event in 20% of these, leaving a number needed to screen of 
462 to postpone one CVD event. Recent evidence suggests the risk reductions from statin therapy 
might be enhanced for those at highest risk15, so this figure may be conservative. 
The results of including a GRS constructed using the results of the CARDIoGRAMplusC4D meta-
analysis in CHD risk prediction have been somewhat disappointing. In the prospective Rotterdam 
study [39] found very limited benefit in the population-wide inclusion of the GRS in risk prediction. 
However, when 103 “suggestively” associated SNPs were included (giving a GRS of 152 SNPs) this 
second score improved the AUC compared to a model including traditional CRFs (although this 
was only statistically significant for prevalent CHD), indicating further gene discovery may 
therefore produce greater improvements. Improvements in both discrimination and 
reclassification were observed in a meta-analysis of six Swedish prospective cohorts [40] and in 
the Malmo Diet and Cancer (MDC) study [41]. Only the reclassification analysis in the MDC study 
was performed using the most recent guidelines however this was based on the US guidelines 
from the ACC/AHA [12] rather than the 10 % high risk cut-off recommended in the most recent 
NICE guidelines in the UK [13]. It has been suggested that due to the nature of case selection in 
GWASs, many of the variants identified in the CARDIoGRAMplusC4D meta-analysis are actually 
associated with CHD survival rather than an incident CHD event itself. This is supported by data 
from both the UCLEB consortium and the Rotterdam study where the gene score was more 
strongly associated with prevalent rather than incident disease [38,39]. This indicates that the 
weightings used may not accurately reflect the impact of each variant on incident CHD risk and 
thus effect sizes obtained from a prospective cohort should be used. This strategy was used by 
Ganna, Magnusson et al. and a better performance was observed with the inclusion of the GRS 
[40].  
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Clinical utility of CHD SNP Gene Scores - Statin Adherence 
One useful consequence of informing at-risk subjects of their genetic risk would be if such 
information motivates lifestyle changes or adherence to proscribed medication to a greater 
extent than CRF information alone.  A clinical trial from the US has examined this [42]. 203 subjects 
(mean age 59 years), at intermediate risk for CHD, and not on statins were randomly assigned to 
receive their 10-year probability of CHD based either on a Framingham CRF score or CRFs+GRS. 
The GRS included 28 CHD GWAS hit SNPs (12 of which are in the top 25 shown in Table 1), with 
each weighted by its published OR effect size. Subjects were told their risk as high or average or 
low by a genetic counsellor, with a discussion about starting statin therapy with a physician. After 
6 months follow-up the +GRS group had 9% lower LDL-C than the CRF group (p=0.04), with 
particular benefit seen in those given a high overall risk. This was because more subjects in the 
high risk group started statin therapy than in the CRF only group (39% vs 22%, p<0.01), and was 
not due to differences between the groups in dietary fat intake or levels of physical activity. These 
data support the view that in a clinical setting, a high genetic risk may be particularly motivating 
to start (and possible adhere to) lipid lowering medication 
 
Clinical utility of CHD SNP Gene Scores - Genetic vs lifestyle 
The GRS can be also used as a genetic instrument to compare the relative contribution of genetic 
and lifestyle factors in determining CHD risk. Using a GRS combining 50 CHD risk variants, Khera 
et al [43]  compared the genetically-determined CHD risk and lifestyle risk in three prospective 
cohorts in the USA and Sweden (total ~56,000 subjects with 5,103 CHD events). A healthy lifestyle 
was defined as a weighted composite of no current smoking, no obesity, regular physical activity, 
and a healthy diet. Results were consistent across the studies and, compared to those in the 
bottom quintile of the GRS, the relative risk of incident CHD in the top quintile was 91% higher 
among those in the top quintile. There was a modest but statistically significant association 
between GRS and a family history of premature CHD (low = 15.1%, intermediate = 16.9% and high 
18.7%, p>0.0001). Unsurprisingly, an unhealthy lifestyle (at least three of the four factors) 
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resulted in a substantially higher (~80%) risk of CHD and the effect of the genetic and lifestyle risk 
was essentially additive. Among those at high genetic risk, a favourable lifestyle was associated 
with a 46% lower CHD relative risk than an unfavourable lifestyle. In a sub-study of 4,260 subjects, 
both genetic and lifestyle factors were significantly associated with coronary artery calcification 
evaluated with computed tomography. One study (ARIC) included enough African-American 
participants (2,269 and 350 CHD events) to show that effects were consistent across ancestral 
groups and were of similar magnitude.   
 
Five year view 
There are several ways the GRS approach will change and develop over the next five years. Firstly, 
there are likely to be improvements in genotyping technology which will allow the use of a very 
large GRS, where every SNP on a genotyping platform could be included. Constructing large-scale 
GRSs using tens of thousands of SNPs with CHD risk estimates (from GWASs) has  been suggested 
[44] . While such a GRS may ultimately out-perform those constructed with only a selected subset 
of robustly associated SNPs, such an approach is not practical for a clinical setting, at least in the 
short-to-medium term. Abraham el al recently published a study [45] using five prospective 
population cohorts from Finland and the US, where over 49,000 SNPs were used. Addition of the 
GRS to CRF scores significantly improved the 10 years risk prediction (P < 0.001), particularly for 
individuals ≥60 years old (p < 0.001). However, how practical this approach will be in the short-to-
medium term remains to be seen. The statistical stringency for inclusion of a SNP could be relaxed 
only partially, by selecting all SNPs identified in the meta-analysis with an false discovery rate of 
say >10%. This approach has been assessed by Gana et al [40], but a 353 SNP GRS did not improve 
performance over the use of 46 robustly associated SNPs. Another approach would be to only 
include variants known to contribute to the process to atherosclerosis and/or of the onset of 
myocardial infarction, and thus a GRS could be created that is  more robustly associated with CHD 
[46] incidence, and this may provide a better instrument to estimate genetic risk of CHD.  
However, this would ignore variants that have been consistently robustly associated with CHD 
with no known no mechanism of action.  Ultimately a large-scale fully powered prospective study 
is required to alleviate the problem of survival bias in genetic association studies. If such data 
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became available this could be used to improve the precision of the weights for the GRS and that 
should improve performance.   
An alternative strategy to using all of the robustly associated GWAS risk variants is to select only 
variants known to be functional, for example by using the ENCODE [47] and eQTL [48] databases 
and protein change algorithms As can be seen in Figure 2 [49], only 7% of the GWAS hits are exonic 
altering an amino-acid in the cognate gene product and therefore may be directly affecting gene 
function, with another 7% being in the promoter region and thus may potentially be affecting 
gene expression. Over 70% are intronic or intergenic and are therefore of unknown or possibly of 
no functional consequence. The most notable such locus is on chromosome 9p21, which has the 
largest effect size of any common variant (see Table 1) but whose mechanism of action in the 
development of CHD remains obscure, a decade after discovery. In particular, the actual 
functional SNP or SNPs at this locus has not been definitively identified.  Thus most of the SNPs 
included in the score are GWAS hits where the lead SNP (i.e. that included in the score) is unlikely 
to be the functional SNP at that risk locus. Linkage disequilbrium (LD) between the lead and 
functional SNPs may differ between ethnicities, meaning that some SNPs will be better proxies 
than others. This will reduce the ability of the weighted GRS to accurately reflect CHD risk, 
particularly in different ethnic groups if the LD is less. Therefore, the second area of progress over 
the next five years will be the identification of the functional SNP (or possibly SNPs) at each risk 
locus, and molecular approaches [49] and guidelines for this process have recently been published  
[50]. 
As an example of this, the Low-Density Lipoprotein Receptor (LDLR) SNP rs6511720 (G>T), located 
in intron-1 of the gene, has been identified in GWAS as being associated with ~0.2mmol/l lower 
plasma levels of LDL-C and a ~12% lower risk of CHD [25]. Whether or not rs6511720 is itself 
functional or a marker for a functional variant elsewhere in the gene is not known. The SNP is in 
complete linkage disequilibrium with three intron-1 SNPs (rs141787760, rs60173709, 
rs57217136), so only one or more than one of these variants may be the functional SNP at this 
locus. Using luciferase reporter assays in the hepatoma cell line Huh7 cells we showed [51] that 
the rare alleles of both rs6511720 and rs57217136 (but not rs60173709) caused a significant 
increase in LDLR expression compared to the common alleles (+29% and +24%, respectively). 
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Multiplex Competitor-Electrophoretic Mobility Shift Assays identified that the transcription factor 
serum response element (SRE) binds to rs6511720, while retinoic acid receptor and signal 
transducer and activator of transcription 1 bind to rs57217136. These data show convincingly that 
both rs6511720 and rs57217136 are functional variants. Both minor alleles create enhancer-
binding protein sites for transcription factors and therefore contribute to increased LDLR 
expression, which is consequently associated with reduced LDL-C levels and 12% lower CHD risk.  
While analysing every GWAS CHD hit locus in this way constitutes a considerable amount of work, 
ultimately this will provide the most accurate panel of functional SNPs for risk prediction. 
Finally we need to be able to extrapolate the use of these GRSs, developed and validated in mainly 
cohorts of white Caucasians, to subjects of different ethnic backgrounds. In comparison to the 
genetics of CHD in those of Europeans ethnicity, very little is known about the genetics of CHD in 
either the South Asian or Afro-Caribbean populations. We have assessed the utility of the 19 SNP 
GRS in two case-control cohorts from Pakistan (Islamabad and Lahore) [35] and one from 
Guadeloupe in the Caribbean [52]. The GRS was higher in Afro-Caribbeans with CHD than in those 
without CHD (13.90 vs 13.17; P < 0.001) and was significantly associated with CHD after 
adjustment for cardiovascular risk factors, with an odds ratio of 1.40 (95% confidence interval, 
1.09-1.80) per standard deviation change. Not surprisingly, there were significant differences in 
allelic distributions between the NPHSII men and the Afro-Caribbean ethnic groups for 14 of the 
19 SNPs, and the GRS was substantially lower in Afro-Caribbean controls compared with white 
controls (13.17 vs 16.59; P < 0.001). By contrast, although the 19 SNP GRS (with the original 
weightings) were higher in cases compared to controls in the Islamabad sample GRS (2.24 v 2.34, 
p=0.04), the score was not associated with CHD after adjustment for age and sex, and there was 
no difference in GRS between cases and controls in the Lahore group. As in the Caribbean sample, 
in the Pakistani samples, risk allele frequencies were significantly lower compared to NPHSII for 
19 SNPs studied. The lack of an association is unlikely to be due to low power, rather, the poor 
performance of the GSs in the Lahore group can be at least partly attributed to the much broader 
definition of CHD used in recruitment the case group compared to the Islamabad study which 
used an MI phenotype (more like the “hard” endpoints used in the prospective NPHSII and the 
Guadeloupe study). Overall, the results indicate that the GSs provide a useful estimate of genetic 
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CHD risk in Afro-Caribbeans from Guadeloupe at least, but firm conclusions cannot be drawn from 
the Pakistani data, although they suggest that a different set of risk loci or SNPs may be required 
for risk prediction in the South Asian population. 
 
Expert Commentary 
In our view, it is now possible to implement a personal Genetic Risk Score, in combination with 
the individual’s CRFs to better risk identify subjects at high risk of future CVD.  The optimum 
number of SNPs to be included and which SNPs to choose, still requires further work, but since 
the OR for individual SNPs are all low, the inclusion or omission of any few SNPs does not appear 
to materially influence the utility of the GRS. We are unaware of any study that compares utility 
of scores that systematically drop or include SNPs that could address this. In the future, the 
technical issues of including a large number of SNPs (with vanishingly small and thus statistically 
unproven CHD risk) should be overcome using more advanced statistical and computational  
approaches. The main clinical utility is a modest improvement in risk stratification in subjects at 
intermediate future CVD risk, where the GRS helps identify subjects at higher than average CVD 
risk that their CRF risk data suggests.  Current data is encouraging that individuals given a high 
genetic risk find the information motivation to modify their behaviours to reduce their future risk. 
The clinical utility of the GS described here depends on the context, as pointed out recently for 
Type 2 Diabetes [34]. If a clinician is trying to predict the risk score of 65 year old men, the GS is 
irrelevant, since the vast majority will qualify for statin treatment under QRISK2 threshold set in 
the current NICE guidelines. By contrast for the age of 40 or 30 or even at birth the situation might 
be different. For example, at birth there will almost never be CRFs of concern but the GS can point 
much further in the future, suggesting that this individual might need to see a doctor when in 
their late thirties instead of past 40, as may otherwise be the case.   
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Key Issues 8-10 Bullet points 
 Classical Risk factor Algorithms such as Framingham and QRISK identify as “high risk” only 
a proportion of those subjects who subsequently go on to develop Coronary Heart Disease 
(CHD) 
 Candidate genes and common variants (SNPs) in these genes have been used to develop 
early Genetic Risk Scores (GRS). 
 The ability to carry out “hypothesis-free” gene discovery by Genome wide association 
studies (GWAS) has now led to the identification of more than 80 CHD risk loci, including 
many of the candidate genes identified earlier 
 These CHD risk SNPs can be combined in a GRS by weighting carriage of the risk allele by 
the meta-analysis effect size (dds Ratio) on CHD. 
 The 25 SNPs ranked by the product of their risk allele frequency and CHD Odds Ratio are 
unlikely to be bettered by any subsequent GWAS findings 
 While a GRS may be associated significantly with CHD risk, for it to have clinical utility it 
must add significantly to the ability of the CRF algorithm to risk stratify. 
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 Metrics to determine clinical utility include the Hosmer-Lemeshow test (to assess 
calibration), Area under the Receiver operating curve, (AROC) and improvement in Net 
Classification Index (NRI). 
 GRS with as few as 19 selected SNPs have been shown to have modest clinical utility in 
middle aged UK men. Inclusion of up to 50-160 additional SNPs gives some small gain in 
clinical utility. 
 Clinical utility is mainly confined to these subjects at intermediate risk as determined by 
CRFs, where subjects who move up a risk category using the GRS do have a high rate of 
future events, and could therefore be offered therapeutic advice. 
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Table 1: Top 25 CARDIoGRAMplusC4D CHD risk loci [25] ranked by ln(OR) multiplied by RAF 
 
RAF = Risk allele frequency. Genes shown in bold are involved in lipid metabolism. * = Loci included in 19 
SNP GRS  
 
 
Chromo
some 
Lead SNP Gene/Locus Odds 
Ratio 
(OR) 
Risk allele 
frequency (RAF) 
ln(OR) 
 x RAF 
19 rs445925 ApoE-ApoC1* 1.13 0.9 0.110 
4 rs7692387 GUCY1A3 1.13 0.81 0.099 
9 rs1333049 9p21* 1.23 0.47 0.097 
1 rs17114036 PPAP2B 1.11 0.91 0.095 
1 rs602633 SORT1* 1.12 0.77 0.087 
10 rs12413409 CYP17A1-CNNM2-NT5C2 1.1 0.89 0.085 
19 rs1122608 LDLR 1.1 0.76 0.072 
13 rs9515203 COL4A1-COL4A2 1.08 0.74 0.057 
9 rs3217992 9p21 1.16 0.38 0.056 
10 rs501120 CXCL12* 1.07 0.83 0.056 
6 rs9369640 PHACTR1 1.09 0.65 0.056 
7 rs11556924 ZC3HC1 1.09 0.65 0.056 
8 rs264 LPL* 1.06 0.86 0.050 
13 rs4773144 COL4A1-COL4A2 1.07 0.74 0.050 
6 rs4252120 PLG 1.07 0.73 0.049 
1 rs11206510 PCSK9* 1.06 0.84 0.049 
1 rs17464857 MIA3* 1.05 0.87 0.042 
1 rs4846525 IL6R 1.09 0.47 0.041 
15 rs7173743 ADAMTS7 1.07 0.58 0.039 
17 rs12936587 RAI1-PEMT-RASD1 1.06 0.59 0.034 
6 rs12205331 ANKS1A 1.04 0.81 0.032 
13 rs9319428 FLT1 1.1 0.32 0.030 
2 rs1561198 VAMP5-VAMP8-GGCX 1.07 0.45 0.030 
12 rs3184504 SH2B3 1.07 0.4 0.027 
8 rs2954029 TRIB1 1.05 0.55 0.027 
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Table 2: Baseline characteristics in NPHSII for those who did and did not go on to develop CHD 
during ten-year follow-up  
 
All variables are presented as the mean plus standard deviation, unless otherwise stated. 
Categorical variables were compared using chi-squared tests and continuous variables were 
compared using Welch’s t-tests, apart from the Framingham and QRISK2 risk scores which were 
compared using Mann Whitney tests (the median and interquartile range are given).  
  
Trait No CHD (n=2491) CHD (n=284) p-value 
Age (years) 55.91 (3.42) 56.64 (3.60) 4.12x10-3 
Sex (% Male) 100 % 100 % - 
Smoking    25 %  39 %  2.14x10-5 
BMI (kg/m2) 26.38 (3.42) 27.19 (3.44) 9.61x10-4 
Systolic Blood Pressure (mmHg) 137.00 (18.59) 144.09 (20.10) 9.68x10-7 
Total Cholesterol (mmol/l) 5.71 (1.01) 6.13 (1.05) 4.79x10-8 
LDL-cholesterol (mmol/l) 3.07 (1.00) 3.48 (0.97) 2.66x10-7 
HDL-cholesterol (mmol/l) 1.72 (0.59) 1.57 (0.53) 2.60x10-4 
Type 2 Diabetes  2 % 7 % 1.33x10-11 
Framingham ten-year CHD risk 0.12 (0.07-0.15) 0.17 (0.09-0.21) 4.33x1011-4 
QRISK2 ten-year CVD risk 0.09 (0.07-0.13) 0.13 (0.09-0.17)  1.93x10-14 
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Table 3: SNPs included in the 19-SNP and 21 SNP CHD risk GRSs.   
 
 
* Included in both the 19 SNP GS and the 21 SNP GS. For detailed methods see [35, 37].  OR = Odds Ratio.  
SNPs in highlighted section were those excluded in the 21 SNP score 
 
 
Table 4 in separate file  
SNPs included in the 19 SNP GS  
 
Gene/Locus  SNP Risk 
Allele 
OR OR in original 
score 
Frequency p-value* Source 
APOE* rs7412 C 1.25 0.80 0.87 - [53]  
APOE* rs429358 C 1.06 1.06 0.26 - [53] 
PCSK9* rs11591147 G 1.39 1.43 0.99 - [54] 
CDKN2A/9p21* rs10757274 G 1.23 1.29 0.47 1.39x10-52 [25]  
SORT1* rs599839 A 1.11 1.19 0.77 3.8x10-15 [25]  
LPA* rs10455872 G 1.32 1.70 0.06 3.80x10-13 [55] 
MIA3* rs17465637 C 1.14 1.14 0.74 1.36x10-8 [55] 
MRAS* rs9818870 T 1.07 1.15 0.14 2.62x10-9 [25]  
CXCL12* rs1746048 C 1.07 1.17 0.83 1.79x10-8 [25]  
LPL* rs328 C 1.09 1.25 0.91 2.34x10-4 [25]  
DAB2IP* rs7025486 A 1.04 1.16 0.29 2.14x10-3 [25]  
LPL* rs1801177 A 1.10 1.33 0.06 4.04x10-4 [25]  
LPA* rs3798220 C 1.28 1.92 0.01 4.90x10-5 [25]  
APOA5* rs662799 G 1.05 1.19 0.06 0.01 [25]  
CETP rs708272 C 1.04 1.28 0.56 0.04 [55] 
ACE rs4341 G 1.01 1.22 0.52 0.43 [55] 
APOB rs1042031 A 1.01 1.73 0.18 0.80 [25]  
NOS3 rs1799983 G 1.00 1.31 0.67 0.90 [55] 
SMAD3 rs17228212 C 1.01 1.21 0.31 0.94 [25]  
Additional SNPs included in the 21 SNP GS  
 
Gene/Locus  SNP Risk 
Allele 
OR 
 
Frequency Source 
GUCY1A3 rs7692387 G 1.13 0.81 [25]  
PPAP2B rs17114036 T 1.11 0.91 [25]  
CYP17A1-
CNNM2-NT5C2 
rs12413409 G 1.10 0.89 [25]  
LDLR rs1122608 G 1.10 0.76 [25]  
COL4A1-COL4A2 rs9515203 T 1.08 0.74 [25]  
PHACTR1 rs9369640f A 1.09 0.65 [25]  
ZC3HC1 Rs11556924 C 1.09 0.65 [25]  
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Figure Legends 
 
Figure 1 Cartoon showing an idealised distribution of the QRISK risk score in the NPHSII men and 
the risk cut-offs recommend for use in the UK by NICE. 1A) using QRISK, 1B) QRISK + GRS 
 
1A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1B 
 
 
 
 
 
 
 
 
 
Foot note. The data is based on a subset of 1213 NPHSII men (mean age 57 years) where 
complete 19 SNP genotype data and QRISK CRF data was available [37]. There were 133 CVD 
events over 13 years of follow up (event rate overall 11.0%). 
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Figure 2  
Pie chart showing the Genomic location of lead SNPs for CAD relative to the nearest gene of 
CHD GWAS hits (from [49]).  Lead SNP data derived from CardioGramPLUSC4D meta-analysis 
[25].  
 
 
